Evolutionary dynamics of escape from biomedical intervention

Proceedings of the Royal Society B: Biological Sciences

Volumn 270, Issue 1533, 2003, Pages 2573-2578

  Iwasa, Yoh ^a   Michor, Franziska ^b   Nowak, Martin A ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Cancer; Drug treatment; HIV; Multi type branching process; Resistance; Vaccination

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR;

DRUG RESISTANCE; EVOLUTION; VACCINATION;

ADAPTATION; ADAPTIVE BEHAVIOR; ANTIBIOTIC RESISTANCE; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; ESCAPE BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR DYNAMICS; PHYLOGENY; PRIORITY JOURNAL; THEORY; VACCINATION; VIRUS LOAD;

EUKARYOTA; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0345830674     PISSN: 09628452     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rspb.2003.2539     Document Type: Article

References (41)

1. Amara, R. R. (and 21 others) 2001 Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74.
2. Anderson, R. M. & May, R. M. 1992 Infectious diseases of humans. Oxford University Press.
3. Athreya, K. B. & Ney, P. E. 1972 Branching processes. New York: Springer.
4. Bonhoeffer, S. & Nowak, M. A. 1997 Pre-existence and emergence of drug resistance in HIV-1 infection. Proc. R. Soc. Lond. B 264, 631-637. (DOI 10.1098/rspb.1997.0089.)
5. Bonhoeffer, S., Lipsitch, M. & Levin, B. R. 1997 Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl Acad. Sci. USA 94, 12 106-12 111.
6. Casado, J. L., Dronda, F., Hertogs, K., Sabido, R., Antela, A., Marti-Belda, P., Dehertogh, P. & Moreno, S. 2001 Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. AIDS Res. Hum. Retroviruses 17, 93-98.
7. Chang, G. & Roth, C. B. 2001 Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 293, 1793-1800.
8. Condra, J. H. (and 15 others) 1995 In-vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571.
9. Desrosiers, R. C. 1998 Prospects for live attenuated HIV. Nature Med. 4, 982.
10. Dittmer, U., Brooks, D. M. & Hasenkrug, K. J. 1999 Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nature Med. 5, 189-193.
11. Eigen, M. & Schuster, P. 1977 The hypercycle. A principle of natural self-organisation. Part A. Emergence of the hypercycle. Naturwissenschaften 64, 541-565.
12. Frank, S. A. 2002 Immunology and evolution of infectious disease. Princeton University Press.
13. Gaschen, B. (and 10 others) 2002 Diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360.
14. Ho, D. & Huang, Y. 2002 The HIV-1 vaccine race. Cell 110, 135-138.
15. Larder, B. A. & Kemp, S. D. 1989 Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246, 1155-1158.
16. Lengauer, C., Kinzler, K. W. & Vogelstein, B. 1998 Genetic instabilities in human cancers. Nature 396, 643-649.
17. Lenski, R. E. 1998 Bacterial evolution and the cost of antibiotic resistance. Int. Microbiol. 1, 265-270.
18. Letvin, N. L. 1998 Progress in the development of an HIV-1 vaccine. Science 280, 1875-1880.
19. Levin, B. R. 2001 Minimizing potential resistance: a population dynamics view. Clin. Inf. Dis. 33, 161-169.
20. Levin, B. R., Lipsitch, M. & Bonhoeffer, S. 1999 Population biology, evolution, and infectious disease: convergence and synthesis. Science 283, 806-809.
21. Levin, B. R., Perrot, V. & Walker, N. 2000 Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154, 985-997.
22. Levy, S. B. 2001 Antibiotic resistance: consequences of inaction. Clin. Inf. Dis. 33, 124-129.
23. Lipsitch, M. 1999 Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerging Inf. Dis. 5, 336-345.
24. Lipsitch, M. 2001 The ups and downs of antimicrobial resistance. Trends Microbiol. 9, 438-444.
25. Lipsitch, M., Bergstrom, C. T. & Levin, B. R. 2000 The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc. Natl Acad. Sci. USA 97, 1938-1943.
26. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E. & Jacks, T. 1994 Status and the efficacy of cancer therapy in vivo. Science 266, 807-810.
27. McCurrach, M. E., Connor, T. M., Knudson, C. M., Korsmeyer, S. J. & Lowe, S. W. 1997 bax-Deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl Acad. Sci. USA 94, 2345-2349.
28. McDonald, B. A. & Linde, C. 2002 Pathogen population genetics, evolutionary potential, and durable resistance. A. Rev. Phytopathol. 40, 349-379.
29. Martinez-Picado, J. (and 15 others) 2000 Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc. Natl Acad. Sci. USA 97, 10 948-10 953.
30. Nowak, M. A. & May, R. M. 2000 Virus dynamics. Oxford University Press.
31. Nowak, M. A., Anderson, R. M., McLean, A. R., Wolfs, T., Goudsmit, J. & May, R. M. 1991 Antigenic diversity thresholds and the development of AIDS. Science 254, 963-969.
32. Nowak, M. A., Bonhoeffer, S., Shaw, G. M. & May, R. M. 1997 Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J. Theor. Biol. 184, 203-217.
33. Nowak, M. A., Komarova, N. L., Sengupta, A., Jallepalli, P. V., Shih, I. M., Vogelstein, B. &Lengauer, C. 2002 The role of chromosomal instability in tumor initiation. Proc. Natl Acad. Sci. USA 99, 16 226-16 231.
34. Ozols, R. F. 1989 Drug resistance in cancer therapy. Dordrecht, The Netherlands: Kluwer.
35. Plotkin, J. B., Dushoff, J. & Levin, S. A. 2002 Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus. Proc. Natl Acad. Sci. USA 99, 6263-6268.
36. Ribeiro, R. M., Bonhoeffer, S. & Nowak, M. A. 1998 The frequency of resistant mutant virus before antiviral therapy. AIDS 12, 461-465.
37. Richie, T. L. & Saul, A. 2002 Progress and challenges for malaria vaccines. Nature 415, 694-701.
38. Richman, D. D. 2001 HIV chemotherapy. Nature 410, 995-1001.
39. Sawyers, C. L. 2001 Research on resistance to cancer drug gleevec. Science 294, 1834.
40. Seneta, E. 1970 Population growth and multi-type Galton-Watson process. Nature 225, 776.
41. Singh Sidhu, A. B., Verdier-Pinard, D. & Fidock, D. A. 2002 Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298, 210-213.